3-(dimethylamino)-1-(2-chlorophenyl)propan-1-one | 91131-19-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(dimethylamino)-1-(2-chlorophenyl)propan-1-one
• 英文别名: o-Chlor-ω-dimethylaminopropiophenon；1-(2-Chlor-phenyl)-3-dimethylamino-propanon-(1)；3-dimethylamino-1-(2-chlorophenyl)-propanone；1-(2-Chlorophenyl)-3-(dimethylamino)propan-1-one
• CAS: 91131-19-0
• 化学式: C₁₁H₁₄ClNO
• 分子量: 211.691
• InChiKey: MERTXJZVANXCIY-UHFFFAOYSA-N

物化性质

• 熔点：
  118 °C
• 沸点：
  279.6±20.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(dimethylamino)-1-(2-chlorophenyl)propan-1-one 在 碘甲烷 作用下， 以 苯 为溶剂， 反应 16.0h， 生成 7-氯-1-茚满酮
  参考文献：
  名称：

  Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA

  摘要：

  A series of ring-substituted analogues of the topoisomerase inhibitor 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides was prepared and evaluated. The compounds were prepared by Pfitzinger reaction of the appropriate isatin-7-carboxylic acids and 1-indanones, followed by selective thermal decarboxylation of the resulting tetracyclic diacids, subsequent oxidation of the methylene group with alkaline permanganate under carefully controlled conditions, and 1,1'-carbonyldiimidazole-induced amidation. The compounds were evaluated in a panel of cell lines in culture. The largest increases in cytotoxicity (five to tenfold) were shown by 4-substituted analogues, with the 4-Cl derivative having an IC50 of 8 nM against the Lewis lung carcinoma. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00231-x
• 作为产物：
  描述：

  2-氯-N-甲氧基-N-甲基苯甲酰胺 、 乙烯基溴化镁 、 二甲胺 以 四氢呋喃 为溶剂， 生成 3-(dimethylamino)-1-(2-chlorophenyl)propan-1-one
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

  摘要：

  A series of 3-aryl-3-azolylpropan-1-amines was prepared and screened for its capability of inhibiting monoamine reuptake. Analogs with nanomolar potency, good human in vitro microsomal stability, and low drug-drug interaction potential were described. In vivo models were used to evaluate the compound 19r for antidepressive, anxiolytic, and analgesic activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.021

文献信息

• NOVEL 5-HT2 ANTAGONISTS
  申请人：AnaMar AB

  公开号：EP3109237A1

  公开（公告）日：2016-12-28

  The present invention relates to 1-amidino-3-aryl-2-pyrazoline derivatives of the general formula I The invention specifically relates to such derivatives which exhibit antagonizing activity towards serotonin 5-HT2B receptors. The present invention also relates to use of said compounds as a medicament and for the treatment of fibrosis, cardiovascular diseases, pain, IBD, and other inflammatory diseases, as well as pharmaceutical compositions comprising one or more of said compounds and methods of treatment.

  本发明涉及通式I的1-酰胺基-3-芳基-2-吡唑啉衍生物。该发明具体涉及表现出对5-HT2B受体具有拮抗活性的这类衍生物。本发明还涉及将所述化合物用作药物以及用于治疗纤维化、心血管疾病、疼痛、炎症性肠病和其他炎症性疾病的用途，以及包含一种或多种所述化合物的药物组合物和治疗方法。
• [EN] UROTENSIN II RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR DE L'UROTENSINE II
  申请人：ACADIA PHARM INC

  公开号：WO2003104216A1

  公开（公告）日：2003-12-18

  Disclosed are compounds of Formula I, or salts or prodrugs thereof, complexed with a human urotensin II receptor as defined herein. Also disclosed are compounds of Formula II, or salts or prodrugs thereof, as defined herein. Also disclosed are methods of modulating the activity of a urotensin II receptor using a compound of Formula I, or a compound of Formula II, or salts or prodrugs thereof. In addition, methods of treating diseases related to the activity of urotensin II receptors are disclosed.

  本文披露了根据本文所定义的与人类尿嘧啶 II 受体形成络合物的 Formula I 化合物，或其盐或前药。还披露了根据本文所定义的 Formula II 化合物，或其盐或前药。还披露了使用 Formula I 化合物、Formula II 化合物、或其盐或前药来调节尿嘧啶 II 受体活性的方法。此外，还披露了治疗与尿嘧啶 II 受体活性相关疾病的方法。
• [EN] TOPOISOMERASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TOPOISOMERASE
  申请人：LATROBE UNIVERSITY

  公开号：WO1998045272A1

  公开（公告）日：1998-10-15

  (EN) The invention provides a novel series of tetracyclic quinoline and quinoxaline carboxamides, $i(bis) compounds in which two of the tetracyclic compounds are joined by a linker, and pharmaceutically-acceptable salts and N-oxides thereof, which have the ability to inhibit topoisomerase activity. The compounds are active $i(in vitro) and $i(in vivo) against tumour cells. Methods of synthesis and pharmaceutical compositions are also claimed.(FR) L'invention concerne une nouvelle série de carboxamides tétracycliques de la quinoline et de la quinoxaline, des composés $i(bis) dans lesquels deux des composés tétracycliques sont reliés par un élément de liaison, ainsi que leurs sels et leurs N-oxydes pharmaceutiquement acceptables, qui sont capables d'inhiber l'activité de la topoisomérase. Ces composés sont actifs $i(in vitro) et $i(in vivo) contre les cellules tumorales. L'invention concerne également des méthodes de synthèse et des compositions pharmaceutiques.

  该发明提供了一种新的四环喹啉和喹噁啉羧酰胺系列化合物，其中两个四环化合物通过连接剂连接形成双重化合物，以及其药学上可接受的盐和N-氧化物，具有抑制拓扑异构酶活性的能力。这些化合物对肿瘤细胞在体内外均具有活性。该发明还涉及合成方法和药学组合物。
• Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1
  申请人：Claremon David A.

  公开号：US20110071139A1

  公开（公告）日：2011-03-24

  This invention relates to novel compounds of the Formula (I), any of the formulas I 1 -I 26 Ia 1-3 -Ij 1-3 or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及公式（I）的新化合物，其中任何公式I1-I26，Ia1-3-Ij1-3或其药学上可接受的盐，以及其制药组合物，用于治疗与哺乳动物中11β-HSD1调节或抑制相关的疾病。本发明还涉及新化合物的制药组合物和它们在细胞中降低或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• CYCLOALKYL LACTAME DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP2254872A2

  公开（公告）日：2010-12-01